We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Biodegradable Joint Implant Targets Arthritis

By HospiMedica International staff writers
Posted on 05 Apr 2012
An innovative biodegradable joint implant is intended for the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA).

Developed by researchers at Tampere University of Technology (TUT; Finland), the RegJoint acts as a spacer in the small joints of the hands and feet, forming a neojoint between adjacent bone ends, thus restoring normal mobility. More...
Made of biodegradable poly-96L/4D-lactide (PLA) copolymer, the porous implant, which is placed inside the joint capsule, stimulates the body to produce connective tissue cells which gradually become replaced by the patient’s own fibroblasts; no separate cell manipulation or culturing is needed prior the operation. RegJoint is manufactured and distributed by Scaffdex (Tampere, Finland).

RA and OA destroy the normally smooth cartilage that lines the ends of bones, reducing mobility and causing pain; as cartilage regenerates poorly, the injuries are difficult to treat. Conventional surgical options involve permanent implants or the artificial induction of joint ossification between two bones.

PLA is a thermoplastic aliphatic polyester derived from renewable resources, such as corn starch (in the United States), tapioca products (roots, chips, or starch, mostly in Asia) or sugarcanes (in the rest of world). PLA is currently used in a number of biomedical applications, such as sutures, stents, dialysis media, and drug delivery devices; it is also being evaluated as an alternative material for tissue engineering.

Related Links:

Tampere University of Technology
Scaffdex



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.